Evidence map›Paper›PMID 35634348›Full record

ReviewFrontiers in immunology2022

Heartbreakers or Healers? Innate Lymphoid Cells in Cardiovascular Disease and Obesity.

Luke B Roberts, Graham M Lord, Jane K Howard

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. (Multi-) omics studies of ILC2s in inflammation and metabolic diseases.Frontiers in cell and developmental biology · 2024
    Review
  3. The inflammatory spectrum of cardiomyopathies.Frontiers in cardiovascular medicine · 2024
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Luke B RobertsSchool of Immunology and Microbial Sciences, King's College London, London, United Kingdom.
Graham M LordSchool of Immunology and Microbial Sciences, King's College London, London, United Kingdom.
Jane K HowardSchool of Cardiovascular and Metabolic Medicine & Sciences, King's College London, London, United Kingdom.
King's College London · GB

Funding

British Heart Foundation PG/12/36/29444Department of HealthMedical Research Council MR/K002996/1Medical Research Council MR/M003493/1Wellcome Trust
6 · The paper itself

Abstract

Cardiovascular diseases (CVDs) are responsible for most pre-mature deaths worldwide, contributing significantly to the global burden of disease and its associated costs to individuals and healthcare systems. Obesity and associated metabolic inflammation underlie development of several major health conditions which act as direct risk factors for development of CVDs. Immune system responses contribute greatly to CVD development and progression, as well as disease resolution. Innate lymphoid cells (ILCs) are a family of helper-like and cytotoxic lymphocytes, typically enriched at barrier sites such as the skin, lung, and gastrointestinal tract. However, recent studies indicate that most solid organs and tissues are home to resident populations of ILCs - including those of the cardiovascular system. Despite their relative rarity, ILCs contribute to many important biological effects during health, whilst promoting inflammatory responses during tissue damage and disease. This mini review will discuss the evidence for pathological and protective roles of ILCs in CVD, and its associated risk factor, obesity.

Indexed as

Cardiovascular DiseasesLymphocytesHumansImmunity, InnateInflammationObesitycardiovascular diseaseheartILCsinnate lymphoid cellsobesity

Identifiers

PMID35634348
PMCPMC9130471
OpenAlexW4280601813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.